| Autor: |
Corbeddu, M., Diociaiuti, A., Vinci, M.R., Santoro, A., Camisa, V., Zaffina, S., El Hachem, M. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Aug2021, Vol. 35 Issue 8, pe483-e485, 3p |
| Abstrakt: |
Numerous skin manifestations associated with COVID-19 infection have been reported so far.1-3 They include vesicular or maculo-papular skin rashes, livedoid/necrotic lesions, urticaria, chilblains-like lesions and drug induced eruptions.1 Clinical trial results for BNT162b2 mRNA Covid-19 vaccine reported mild-to-moderate pain at the injection site within 7 days after administration, with severe pain in <1% of participants and redness or swelling in a lower percentage. Among these cases, 38% (11 patients), reported in Table 1, developed cutaneous symptoms, such as erythemato-oedematous reaction at injection site, diffuse morbilliform rash, mild erythema and positive dermographism (Fig. Although the majority of patients (72.7%, eight cases) had a previous history of allergy or allergic diathesis, the skin reactions were very mild. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text